Health ยท Democratic Republic of the Congo

Two Bundibugyo-Specific Ebola Vaccine Candidates Cleared for Phase 2 Trials in DR Congo

The WHO says two vaccine candidates developed specifically for the Bundibugyo Ebola virus have been approved to move into phase 2 of the Tumani trial in DR Congo. Testing is expected to begin in Bunia on 26 or 27 November, as the outbreak tops 11,300 cases.

Two experimental vaccines designed specifically against the Bundibugyo strain of Ebola are expected to begin phase 2 clinical trials in the Democratic Republic of the Congo next week, the World Health Organization said at a news conference in Geneva on Tuesday.

WHO official Dr Meg Doherty said both candidates were approved last week to advance to the second phase of the Tumani randomised controlled trial. One vaccine, ChAdOx1, was developed by Oxford University and the Serum Institute of India. The other was developed by Moderna. Doherty said testing was expected to start on 26 or 27 November in Bunia, where the trial is under way.

Phase 2 will assess the vaccines' safety and immunogenicity, meaning their ability to trigger an immune response. Candidates that meet the required criteria will then move to phase 3, where researchers will compare their effectiveness against a comparator.

The Tumani trial was launched on 23 October and is designed to take in further vaccine candidates as they become available. Doherty said more than 140 participants have enrolled so far. Thousands are expected to take part as researchers extend testing to more sites and deploy mobile teams.

WHO Director-General Tedros Adhanom Ghebreyesus said the two candidates could begin testing as early as next week. He said the outbreak has passed 11,300 cases and 5,500 deaths, with between 400 and 500 new infections still reported each week.

Tedros warned that insecurity, attacks on health workers and delays in identifying infections continue to undermine efforts to contain the epidemic. He said such attacks also discourage people from seeking care at Ebola treatment centres.

More reporting from Voice of Africans